Posicor

Known as: Roche Brand of Mibefradil Dihydrochloride 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2016
01219862016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was… (More)
Is this relevant?
2002
2002
BACKGROUND Mibefradil is a T-type calcium-channel antagonist and arterial vasodilator with negative chronotropic effects. It is… (More)
Is this relevant?
Review
2000
Review
2000
Mibefradil is a tetralol derivative chemically distinct from other calcium channel antagonists. It is a very effective… (More)
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • figure 4
Is this relevant?
Review
2000
Review
2000
At supratherapeutic doses (2to 5-fold), the T-type Ca antagonist mibefradil modifies the T/U wave of the human ECG. In this study… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
1998
1998
 
Is this relevant?
1998
1998
 
Is this relevant?
1998
1998
 
Is this relevant?
Review
1997
Review
1997
 
Is this relevant?
1987
1987
Survival in severe left ventricular failure is poor but has not been widely assessed since the introduction of several new… (More)
Is this relevant?
1986
1986
The end-systolic pressure-volume relation has been postulated as a load-independent measure of cardiac contractility, but has… (More)
Is this relevant?